The U.S. JPML determined that allegations raised in a number of insulin price fixing lawsuits each arise from a common factual core, which makes consolidation of the cases before one federal judge appropriate.
Five separate states have filed insulin pricing scheme lawsuits against drug manufacturers, and are calling for the cases to be consolidated in a Mississippi federal court.
Lawsuits allege the insulin pricing scheme leads to states and consumers paying $300 to $700 for doses, which cost the drug makers just $2 to produce.
Rebates disguised as "administrative fees" and other costs lead to an illegal insulin pricing scheme which costs consumers and the healthcare system billions of dollars, the lawsuit claims
